Skip to main content
SpringerLink
Log in

Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages

A retrospective study identifying subgroups of different prognoses by using the RECPAM method

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

In chronic idiopathic myelofibrosis (CIMF) the factors predicting survival in patients who were already in the fibrotic stage have been well documented by numerous studies. Prefibrotic stages were only rarely evaluated so that the prognostic impact of myelofibrosis is currently not well known. Also predictive factors for disease-related events were not included in those studies. Thus, we evaluated the prognostic impact of myelofibrosis and other histopathological (megakaryocytes, blasts) and clinical [age, gender, splenomegaly, chemotherapy, hemoglobin (Hb), leukocyte, and platelet count] parameters in 122 patients in fibrotic and prefibrotic stages of CIMF on event-free survival. The statistical analysis was performed using the univariate log-rank test and the multivariate recursive partition and amalgamation (RECPAM) approach. In 62 patients disease-related events occurred during a mean observation period of 58 months. In univariate analysis they were associated with blast increase in the bone marrow. In RECPAM analysis a shorter event-free survival was found in anemic patients (mean: 9.3 months). In nonanemic patients older than 60 years, advanced myelofibrosis was associated with a shorter event-free mean survival of 23.2 months versus 69.3 months in less advanced cases. A slight or moderate myelofibrosis was not found to have a prognostic impact on event-free survival. The longest event-free survival was found in nonanemic patients who were younger than 60 years (mean: 185 months), regardless of the grade of myelofibrosis. Thus, we found that the most relevant prognostic parameter for event-free survival in CIMF were the Hb value, age, and grade of myelofibrosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1a–d.
Fig. 2a–d.
Fig. 3.

Similar content being viewed by others

References

  1. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E (1988) A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70:397–401

    CAS  PubMed  Google Scholar 

  2. Brodmann S, Passweg JR, Gratwohl A, Tichelli A, Skoda RC (2000) Myeloproliferative disorders: complications, survival and causes of death. Ann Hematol 79:312–318

    Article  CAS  PubMed  Google Scholar 

  3. Buhr T, Büsche G, Choritz H, Länger F, Kreipe H (2002) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced by sequential bone marrow biopsies. Am J Clin Pathol 119:152–158

    Google Scholar 

  4. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E (1998) The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 60:101–105

    CAS  PubMed  Google Scholar 

  5. Cervantes F, Pereira A, Esteve J, Ravel M, Cobo F, Rozman C, Montserrat E (1997) Identification of "short lived" and "long lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 97:635–640

    CAS  PubMed  Google Scholar 

  6. Ciampi A, Hogg SH, McKinney S, Thiffault J (1988) RECPAM: a computer program for recursive partition and amalgamation for censored survival data and other situations frequently occurring in biostatistics. Comput Methods Programs Biomed 26:239–256

    CAS  PubMed  Google Scholar 

  7. Ciampi A, Negassa A, Lou Z (1995) Tree-structured prediction for censored survival data and the Cox model. J Clin Epidemiol 48:675–689

    Article  CAS  PubMed  Google Scholar 

  8. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88:1013–1018

    CAS  PubMed  Google Scholar 

  9. Georgii A, Büsche G, Kreft A (1998) The histopathology of chronic myeloproliferative diseases. Baillieres Clin Haematol 11:721–749

    CAS  PubMed  Google Scholar 

  10. Hasselbach H, Jensen BA (1990) Prognostic factors in idiopathic myelofibrosis: a simple clinical scoring system with prognostic significance. Eur J Haematol 44:172–178

    PubMed  Google Scholar 

  11. Hasselbach H, Lisse IA (1991) A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur J Haematol 46:285–289

    CAS  PubMed  Google Scholar 

  12. Kreft A, Reimann J, Choritz H (2000) Fibre content and cellularity of the bone marrow of the iliac crest, vertebral column and sternum in chronic myeloproliferative disorders. Leuk Lymphoma 38:165–173

    CAS  PubMed  Google Scholar 

  13. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R (1997) Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 80:708–719

    Article  CAS  PubMed  Google Scholar 

  14. Michiels JJ, Thiele J (2002) Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 76:133–145

    PubMed  Google Scholar 

  15. Njoku OS, Lewis SM, Catovsky D (1983) Anaemia in myelofibrosis: its value of prognosis. Br J Haematol 54:79–89

    CAS  PubMed  Google Scholar 

  16. Okamura T, Kinukawa N, Niho Y, Mizoguchi H (2001) Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73:194–198

    CAS  PubMed  Google Scholar 

  17. Pereira A, Cervantes F, Brugues R, Rozman C (1990) Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol 44:94–98

    Google Scholar 

  18. Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A (1997) Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98:96–102

    CAS  PubMed  Google Scholar 

  19. Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, D'Amico S, Cinciripini A, Leoni P (1994) Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 68:205–212

    CAS  PubMed  Google Scholar 

  20. Tefferi A, Mesa R, Nagorney DM, Schroeder G, Silverstein MN (2000) Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95:2226–2233

    CAS  PubMed  Google Scholar 

  21. Thiele J, Kvasnicka HM, Diehl V, Fischer R, Michiels JJ (1999) Clinicopathological diagnosis and differential criteria of thrombocythemia in various myeloproliferative disorders by histopathology, histochemistry and immunostainings from bone marrow biopsies. Leuk Lymphoma 33:207–218

    CAS  PubMed  Google Scholar 

  22. Thiele J, Kvasnicka HM, Zankovich R, Diehl V (2002) Early-stage idiopathic (primary) myelofibrosis—current issues of diagnostic features. Leuk Lymphoma 43:1035–1041

    Google Scholar 

  23. Thiele J, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G (2001) Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumors: pathology and genetics of tumours of the haematopoetic and lymphoid tissues. IARC Press, Lyon, pp 35–38

  24. Varki A, Lottenberg R, Griffith R, Reinhard E (1983) The syndrome of idiopathic myelofibrosis: a clinicopathological review with emphasis on the prognostic variables predicting survival. Medicine 62:353–371

    CAS  PubMed  Google Scholar 

  25. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Latagliata R, Pileri S, Margrini U, Gugliotta L, Morra E, Bernasconi C, Mandelli F, Tura S (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4–9

    CAS  PubMed  Google Scholar 

  26. Wehmeier A, Daum I, Jamin H, Schneider W (1991) Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. Ann Hematol 63:101–106

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Medizinische Hochschule, 30652, Hannover, Germany

    A. Kreft, M. Weiß, H. Choritz, T. Buhr, G. Büsche & A. Georgii

  2. Institut für Pathologie, Klinikum Johannes Gutenberg Universität, Langenbeckstrasse 1, 55101, Mainz, Germany

    A. Kreft

  3. Institut für Biometrie, Medizinische Hochschule, Hannover, Germany

    B. Wiese

Authors
  1. A. Kreft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Weiß
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Wiese
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Choritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Buhr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Büsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Georgii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Kreft.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kreft, A., Weiß, M., Wiese, B. et al. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. Ann Hematol 82, 605–611 (2003). https://doi.org/10.1007/s00277-003-0719-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0719-9

Keywords

Search

Navigation